FrancophonIA/ELRC3.0 huggingface dataset:
English: What are the risks associated with Izba?
Croatian: Koji su rizici povezani s lijekom Izba?
English: Why is Izba approved?
Croatian: Zašto je lijek Izba odobren?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Izba on 20 February 2014.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Izba na snazi u Europskoj uniji od 20. veljače 2014.
English: This helps to reduce the pressure inside the eye.
Croatian: Time pomaže u snižavanju očnog tlaka.
English: It was calculated that Izba used in children would result in a similar reduction in pressure.
Croatian: Izračunato je da bi se primjenom lijeka Izba u djece postiglo slično sniženje tlaka.
English: In patients taking Izba, the average eye pressure (measured at 8 am in the morning) was 19.4, 19.3 and 19.2 mmHg following 2 weeks, 6 weeks and 3 months of treatment, respectively, which matched the pressure seen at similar time points in patients taking Travatan (19.5, 19.3 and 19.3 mmHg).
Croatian: U bolesnika koji su primali lijek Izba prosječan očni tlak (izmjeren u 8 sati ujutro) bio je 19,4 mmHg nakon 2 tjedna terapije, 19,3 mmHg nakon 6 tjedana te 19,2 mmHg nakon 3 mjeseca, što je odgovaralo tlaku izmjerenom otprilike u isto vrijeme u bolesnika koji su primali Travatan (19,5 mmHg, 19,3 mmHg i 19,3 mmHg).
English: This is a summary of the European public assessment report (EPAR) for Izba.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Izba.
English: It is not intended to provide practical advice on how to use Izba.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Izba.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Izba's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Izba nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: The active substance in Izba, travoprost, is a prostaglandin analogue (a man-made version of a prostaglandin, substances naturally found in the body).
Croatian: Djelatna tvar lijeka Izba, travoprost, analog je prostaglandina (umjetna inačica prostaglandina, tvari koja se prirodno nalazi u tijelu).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Izba have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Izba nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: By lowering the pressure, Izba reduces the risk of damage.
Croatian: Izba snižava tlak i na taj način smanjuje rizik od oštećenja.
English: Other information about Izba
Croatian: Ostale informacije o lijeku Izba
English: In the study of children with glaucoma or ocular hypertension given Travatan, the average eye pressure was reduced by around 27% after 12 weeks.
Croatian: U ispitivanju kojim su bila obuhvaćena djeca s glaukomom ili povišenim očnim tlakom koja su primala lijek Travatan prosječan očni tlak snižen je za oko 27 % nakon 12 tjedana.
English: It can also be used in children from 3 years of age who have ocular hypertension or childhood glaucoma.
Croatian: Može se primjenjivati i u djece starije od 3 godine koja imaju povišen očni tlak ili boluju od dječjeg glaukoma
English: The study showed that Izba was as effective as Travatan at reducing pressure in the eye following 2 weeks, 6 weeks and 3 months of treatment.
Croatian: Ispitivanjem je dokazano da je lijek Izba jednako djelotvoran kao i Travatan u snižavanju očnog tlaka nakon terapije u trajanju od 2 tjedna, 6 tjedana i 3 mjeseca.
English: Izba (30 microgram/ml) has been investigated in a main study involving 864 patients with open-angle glaucoma or ocular hypertension, whose average eye pressure was 27 mmHg.
Croatian: Lijek Izba (30 mikrograma/ml) ispitan je u glavnom ispitivanju kojim je bilo obuhvaćeno 864 bolesnika oboljelih od glaukoma otvorenog kuta ili s povišenim očnim tlakom u kojih je prosječni očni tlak bio 27 mmHg.
English: How is Izba used?
Croatian: Kako se Izba koristi?
English: In the eye, prostaglandins increase the drainage of the watery fluid (aqueous humour) out of the eyeball.
Croatian: Unutar oka prostaglandini pojačavaju otjecanje tekućine (očne vodice) iz očne jabučice.
English: Izba is an eye-drop solution that is used to reduce intraocular pressure (pressure inside the eye) in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) and in adults with ocular hypertension (when the pressure in the eye is higher than normal).
Croatian: Izba je otopina za kapi za oči koja se primjenjuje radi snižavanja intraokularnog (očnog) tlaka u odraslih osoba koje boluju od glaukoma otvorenog kuta (bolesti pri kojoj očni tlak raste zbog nemogućnosti otjecanja očne vodice) te u odraslih osoba koje imaju povišen očni tlak (stanje pri kojem je očni tlak viši od normalnog).
English: Izba contains the active substance travoprost.
Croatian: Izba sadržava djelatnu tvar travoprost.
English: When pressure in the eye is raised, it can cause damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Croatian: Povišen očni tlak može izazvati oštećenje mrežnice (membrane osjetljive na svjetlost smještene u stražnjem dijelu očne jabučice) i očnog živca kojim se iz oka šalju signali prema mozgu.
English: The safety profile of Izba seemed more favourable than that of the higher-strength solution, as side effects were less frequent with Izba.
Croatian: Sigurnosni profil lijeka Izba činio se povoljnijim od onoga otopine u jačoj koncentraciji jer su nuspojave prilikom primjene lijeka Izba bile manje učestale.
English: Both medicines were given as one drop in the affected eye once a day, in the evening.
Croatian: Oba su lijeka davana u dozi od jedne kapi u zahvaćeno oko jednom dnevno, i to uvečer.
English: The CHMP noted that Izba 30 microgram/ml is as effective as the 40 microgram/ml solution of travoprost.
Croatian: CHMP je napomenuo da je lijek Izba u koncentraciji od 30 mikrograma/ml jednako djelotvoran kao i otopina travoprosta u koncentraciji od 40 mikrograma/ml.
English: Izba is available as an eye-drop solution (30 microgram/ml) and can only be obtained with a prescription.
Croatian: Lijek Izba dostupan je u obliku otopine za kapi za oči (30 mikrograma/ml) i izdaje se samo na liječnički recept.
English: Izba acts in the same way and increases the flow of fluid out of the eye.
Croatian: Izba djeluje na isti način te pojačava istjecanje tekućine iz oka.
English: For more information about treatment with Izba, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Izba pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svojem liječniku ili ljekarniku.
English: For practical information about using Izba, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Izba bolesnici trebaju pročitati u uputi o lijeku, odnosno trebaju se obratiti svojem liječniku ili ljekarniku.
English: How does Izba work?
Croatian: Kako djeluje Izba?
English: Evidence from studies with Izba in adults and with Travatan in children has also been used to work out the effectiveness of Izba in children.
Croatian: Dokazi iz ispitivanja lijeka Izba među odraslim osobama i lijeka Travatan među djecom poslužili su i kao temelj za donošenje zaključaka o djelotvornosti lijeka Izba u djece.
English: The most common side effect with Izba (which may affect more than 1 in 10 people) is ocular hyperaemia (increased blood supply to the eye, leading to eye irritation and redness)
Croatian: Najčešća nuspojava pri primjeni lijeka Izba (koja se može javiti u više od 1 na 10 bolesnika) je okularna hiperemija (povećan dotok krvi u oko što dovodi do nadraženosti i crvenila oka).
English: What benefits of Izba have been shown in studies?
Croatian: Koje su koristi lijeka Izba dokazane u ispitivanjima?
English: The dose is one drop of Izba in the affected eye(s) once a day, preferably in the evening.
Croatian: Doza je jedna kap u zahvaćeno oko/zahvaćene oči jednom dnevno, po mogućnosti uvečer.
English: An eye-drop solution containing travoprost at a concentration of 40 microgram/ml has been already authorised in the EU as Travatan since 2001.
Croatian: Od 2001. u EU-u je na snazi odobrenje za Travatan, drugu otopinu za kapi za oči koja sadržava travoprost u koncentraciji od 40 mikrograma/ml.
English: Izba is expected to be effective and safe in children from 3 years of age, based on adult studies and a study of 40 microgram/ml travoprost solution in children.
Croatian: Na temelju rezultata ispitivanja provedenih među odraslim osobama i ispitivanja otopine koja sadržava travoprost u koncentraciji od 40 mikrograma/ml, očekuje se da će lijek Izba biti djelotvoran i siguran za primjenu u djece starije od 3 godine.
English: You can inhale this medicine any time before or after food or drink.
Croatian: Možete inhalirati ovaj lijek u bilo kojem trenutku prije ili nakon uzimanja hrane ili pića.
English: Date of first authorisation: 28 September 2012 Date of latest renewal: 19 July 2017
Croatian: Datum posljednje obnove odobrenja: 19. srpnja 2017.
English: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a signifcant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Croatian: • prilikom svake izmjene sustava za upravljanje rizikom, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera koristi/rizik, odnosno kada je izmjena rezultat ostvarenja nekog važnog cilja (u smislu farmakovigilancije ili minimizacije rizika).
English: • Seebri Breezhaler capsules must always be stored in the blister card and only removed immediately before use.
Croatian: • Seebri Breezhaler kapsule moraju se uvijek čuvati u blister kartici i izvaditi tek neposredno prije primjene.
English: Seebri Breezhaler can be used at the recommended dose in elderly patients (75 years of age and older) (see section 4.8).
Croatian: Seebri Breezhaler se može koristiti u preporučenoj dozi u starijih bolesnika (u dobi od 75 i više godina) (vidjeti dio 4.8).
English: How to inhale Seebri Breezhaler - In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder.
Croatian: Kako inhalirati Seebri Breezhaler - U ovom pakiranju naći ćete inhalator i kapsule (u blisterima) koji sadrže lijek kao prašak inhalata.
English: Patients should be informed about the signs and symptoms of acute narrow-angle glaucoma and should be informed to stop using Seebri Breezhaler and to contact their doctor immediately should any of these signs or symptoms develop.
Croatian: Bolesnike treba obavijestiti o znakovima i simptomima akutnog glaukoma uskog kuta i uputiti ih da prestanu koristiti Seebri Breezhaler te da se odmah obrate svom liječniku ako se pojavi bilo koji od tih znakova i simptoma.
English: The recommended dose is the inhalation of the content of one capsule once daily using the Seebri Breezhaler inhaler.
Croatian: Preporučena doza je inhalacija sadržaja jedne kapsule jedanput na dan korištenjem Seebri Breezhaler inhalatora.
English: The European Medicines Agency has waived the obligation to submit the results of studies with Seebri Breezhaler in all subsets of the paediatric population in COPD (see section 4.2 for information on paediatric use).
Croatian: Europska agencija za lijekove izuzela je obvezu podnošenja rezultata ispitivanja lijeka Seebri Breezhaler u svim podskupinama pedijatrijske populacije u KOPB-u (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
English: - When you start a new pack, use the new Seebri Breezhaler inhaler that is supplied in the pack.
Croatian: - Kada otvorite novo pakiranje, upotrijebite novi Seebri Breezhaler inhalator koji je priložen u pakiranju.
English: The capsules must be administered only using the Seebri Breezhaler inhaler (see section 6.6).
Croatian: Kapsule se moraju primjenjivati isključivo korištenjem Seebri Breezhaler inhalatora (vidjeti dio 6.6).
English: There is no relevant use of Seebri Breezhaler in the paediatric population (under 18 years) in the indication COPD.
Croatian: Nema relevantne primjene Seebri Breezhalera u pedijatrijskoj populaciji (mlađih od 18 godina) u indikaciji KOPB-a.
English: In clinical studies with Seebri Breezhaler, paradoxical bronchospasm was not observed.
Croatian: U kliničkim ispitivanjima sa Seebri Breezhalerom nije bio uočen paradoksalni bronhospazam.
English: There are no data from the use of Seebri Breezhaler in pregnant women.
Croatian: Nema podataka o primjeni Seebri Breezhaler u trudnica.
English: The long duration of action can be partly attributed to sustained concentrations of active substance in the lung as reflected by the prolonged terminal elimination half-life of glycopyrronium after inhalation via the Seebri Breezhaler inhaler in contrast to the half life after intravenous administration (see section 5.2).
Croatian: Dugo trajanje djelovanja djelomično se može pripisati održanim koncentracijama djelatne tvari u plućima što se odražava produljenim terminalnim poluvijekom eliminacije glikopironija nakon inhalacije putem Seebri Breezhaler inhalatora za razliku od poluvijeka nakon intravenske primjene (vidjeti dio 5.2).
English: No change in mean heart rate or QTc interval was observed with Seebri Breezhaler in doses up to 176 micrograms in COPD patients.
Croatian: Nije bila uočena nikakva promjena u srednjoj srčanoj frekvenciji ili QTc intervalu sa Seebri Breezhalerom u dozama do 176 mikrograma u bolesnika s KOPB-om.
English: What Seebri Breezhaler is and what it is used for What you need to know before you use Seebri Breezhaler How to use Seebri Breezhaler Possible side effects
Croatian: Što je Seebri Breezhaler i za što se koristi Što morate znati prije nego počnete primjenjivati Seebri Breezhaler Kako primjenjivati Seebri Breezhaler Moguće nuspojave
English: Following oral inhalation using the Seebri Breezhaler inhaler, glycopyrronium was rapidly absorbed and reached peak plasma levels at 5 minutes post dose.
Croatian: Nakon oralne inhalacije korištenjem Seebri Breezhaler inhalatora, glikopironij se brzo apsorbirao i dosegnuo vršne razine u plazmi 5 minuta nakon doze.
English: During treatment with Seebri Breezhaler, stop taking this medicine and tell your doctor immediately: - if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Seebri Breezhaler (signs of bronchospasm).
Croatian: Tijekom liječenja Seebri Breezhalerom prestanite primjenjivati ovaj lijek i odmah se obratite liječniku: - ako osjetite stezanje u prsnom košu, kašljanje, piskanje ili nedostatak zraka odmah nakon primjene Seebri Breezhalera (znakovi bronhospazma).
English: Although no formal drug interaction studies have been performed, Seebri Breezhaler has been used concomitantly with other medicinal products commonly used in the treatment of COPD without clinical evidence of drug interactions.
Croatian: Iako nisu provedena formalna ispitivanja interakcija među lijekovima, Seebri Breehaler je istodobno primjenjivan s drugim lijekovima koji se često primjenjuju u liječenju KOPB-a bez kliničkog dokaza o interakcijama među lijekovima.
English: Seebri Breezhaler is recommended to be administered, at the same time of the day each day.
Croatian: Preporučuje se da se Seebri Breezhaler primjenjuje u isto vrijeme svakoga dana.
English: Seebri Breezhaler once daily has also shown a statistically significant effect on health-related quality of life measured using the St. George's Respiratory Questionnaire (SGRQ).
Croatian: Seebri Breezhaler jedanput na dan također je pokazao statistički značajan učinak na kvalitetu života povezanu sa zdravljem mjerenu korištenjem „St. George“ respiratornog upitnika (eng.
English: Seebri Breezhaler 44 micrograms once daily provided consistently statistically significant improvement in lung function (forced expiratory volume in one second, FEV1, forced vital capacity, FVC, and inspiratory capacity, IC) in a number of clinical studies.
Croatian: Seebri Breezhaler 44 mikrograma jedanput na dan omogućio je dosljedno statistički značajno poboljšanje plućne funkcije (forsirani izdisajni volumen u jednoj sekundi, FEV1, forsirani vitalni kapacitet, FVC, i inspiratorni kapacitet, IC) u više kliničkih ispitivanja.
English: Seebri Breezhaler should be used with caution in these patient groups.
Croatian: Seebri Breezhaler treba oprezno koristiti u tih skupina bolesnika.
English: Seebri Breezhaler 44 micrograms once daily can be safely used in all age and body weight groups.
Croatian: Seebri Breezhaler 44 mikrograma jedanput na dan može se sigurno primjenjivati u svim dobnim skupinama i skupinama prema tjelesnoj težini.
English: Please read the full Instructions for Use before using the Seebri Breezhaler.
Croatian: Pročitajte u cijelosti Upute za primjenu prije korištenja Seebri Breezhalera.
English: The co-administration of Seebri Breezhaler with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Croatian: Istodobna primjena Seebri Breezhalera s drugim lijekovima koji sadrže antikolinergike nije bila proučavana pa se stoga ne preporučuje.
English: In a 3-week study where exercise tolerance was tested via cycle ergometer at submaximal (80%) workload (submaximal exercise tolerance test), Seebri Breezhaler, dosed in the morning, reduced dynamic hyperinflation and improved the length of time exercise could be maintained from the first dose onwards.
Croatian: U 3-tjednom ispitivanju gdje je tolerancija napora bila ispitivana pomoću biciklergometra pri submaksimalnom (80%) opterećenju (submaksimalni test tolerancije napora), Seebri Breezhaler, primijenjen ujutro, smanjio je dinamičku hiperinflaciju i poboljšao duljinu vremena tijekom kojeg se mogao održavati napor od prve doze nadalje.
English: Talk to your doctor before using Seebri Breezhaler, if any of the following applies to you: - you have kidney problems.
Croatian: Obratite se svom liječniku prije nego primijenite Seebri Breezhaler, ako se bilo što od navedenoga u nastavku odnosi na Vas: - ako imate tegobe s bubrezima.
English: Acute intoxication by inadvertent oral ingestion of Seebri Breezhaler capsules is unlikely due to the low oral bioavailability (about 5%).
Croatian: Akutna intoksikacija slučajnim oralnim unosom kapsula Seebri Breezhaler malo je vjerojatna zbog niske oralne bioraspoloživosti (oko 5%).
English: This includes medicines similar to Seebri Breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium (so called anticholinergics).
Croatian: To uključuje lijekove koji su slični Seebri Breezhaleru i koriste se za Vašu plućnu bolest, kao što su ipratropij, oksitropij ili tiotropij (takozvani antikolinergici).
English: The absolute bioavailability of glycopyrromium inhaled via Seebri Breezhaler was estimated to be about 45% of the delivered dose.
Croatian: Procijenjeno je da je apsolutna bioraspoloživost glikopironija inhaliranog preko Seebri Breezhalera oko 45% isporučene doze.
English: 6 or 10 Seebri Breezhaler capsules to be used in the inhaler
Croatian: 6 ili 10 Seebri Breezhaler kapsula za korištenje u inhalatoru
English: No specific side effects have been reported when Seebri Breezhaler has been used together with other medicines used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).
Croatian: Nisu prijavljene posebne nuspojave kada se Seebri Breezhaler primjenjivao istodobno s drugim lijekovima koji se primjenjuju za liječenje KOPB-a kao što su inhalatori za olakšavanje tegoba (npr. salbutamol), metilksantini (npr. teofilin) i/ili oralni i inhalacijski steroidi (npr. prednizolon).
English: What Seebri Breezhaler contains - The active substance is glycopyrronium bromide.
Croatian: Što Seebri Breezhaler sadrži - Djelatna tvar je glikopironijev bromid.
English: If you use more Seebri Breezhaler than you should If you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit.
Croatian: Ako ste inhalirali previše ovog lijeka ili ako netko zabunom uzme Vaše kapsule, morate odmah obavijestiti svog liječnika ili otići u najbližu hitnu pomoć.
English: In COPD patients with mild and moderate renal impairment (estimated glomerular filtration rate, eGFR ≥30 ml/min/1.73 m2) Seebri Breezhaler can be used at the recommended dose.
Croatian: U bolesnika s KOPB-om i s blagim i umjerenim oštećenjem bubrega (procijenjena glomerularna filtracija, eGFR ≥30 ml/min/1,73 m2) Seebri Breezhaler može se koristiti pri preporučenoj dozi.
English: In the pooled 6-month database the frequency of dry mouth was 2.2% versus 1.1%, of insomnia 1.0% versus 0.8%, and of gastroenteritis 1.4% versus 0.9%, for Seebri Breezhaler and placebo respectively.
Croatian: U bazi objedinjenih 6-mjesečnih podataka učestalost suhih usta bila je 2,2% naspram 1,1%, nesanice 1,0% naspram 0,8%, te gastroenteritisa 1,4% naspram 0,9% za Seebri Breezhaler odnosno placebo.
English: Seebri Breezhaler is used as a maintenance treatment for your COPD.
Croatian: Seebri Breezhaler se koristi kao terapija održavanja za Vaš KOPB.
English: PA/Alu/PVC - Alu perforated unit-dose blister Packs containing 6x1, 10x1, 12x1 or 30x1 hard capsules, together with one inhaler.
Croatian: PA/Al/PVC - Aluminijski perforirani blister djeljiv na jedinične doze Pakiranje sadrži 6x1, 10x1, 12x1 ili 30x1 tvrdih kapsula, zajedno s jednim inhalatorom.
English: Seebri Breezhaler is a once-daily, long-term maintenance treatment and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e. as a rescue therapy.
Croatian: Seebri Breezhaler je dugoročna terapija održavanja koja se primjenjuje jedanput na dan i nije indiciran za inicijalno liječenje akutnih epizoda bronhospazama, tj. za hitno ublažavanje simptoma.
English: After three weeks of treatment the improvement in inspiratory capacity with Seebri Breezhaler was similar to the first day (200 ml), exercise endurance time however had increased by 89 seconds (an increase of 21%) compared to placebo.
Croatian: Nakon tri tjedna liječenja poboljšanje u inspiratornom kapacitetu sa Seebri Breezhalerom bilo je slično onome za prvi dan (200 ml), vrijeme izdržavanja napora se, međutim, povećalo za 89 sekundi (povećanje od 21%) u usporedbi s placebom.
English: Peak plasma levels and total systemic exposure following intravenous administration of 150 micrograms glycopyrronium bromide (equivalent to 120 micrograms glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total exposure at steady-state achieved with the recommended dose (44 micrograms once daily) of Seebri Breezhaler and were well tolerated.
Croatian: Vršne razine u plazmi i ukupna sistemska izloženost nakon primjene u venu 150 mikrograma glikopironijevog bromida (što je ekvivalentno 120 mikrograma glikopironija) u zdravih dobrovoljaca bile su oko 50 odnosno 6 puta više od vršne i ukupne izloženosti u stanju dinamičke ravnoteže postignute uz preporučenu dozu (44 mikrograma jedanput na dan) Seebri Breezhalera i dobro su se podnosile.
English: Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Croatian: Seebri Breezhaler je indiciran kao bronhodilatacijska terapija održavanja za ublažavanje simptoma u odraslih bolesnika s kroničnom opstruktivnom plućnom bolešću (KOPB).